Antiemetic Prophylaxis with Fosaprepitant and 5-HT
Adolescent
Antibiotic Prophylaxis
Antiemetics
/ administration & dosage
Child
Child, Preschool
Female
Hematopoietic Stem Cell Transplantation
Humans
Infant
Male
Morpholines
/ administration & dosage
Neoplasms
/ therapy
Retrospective Studies
Serotonin 5-HT3 Receptor Antagonists
/ administration & dosage
Transplantation, Autologous
5-HT3-antagonists
antiemetic prophylaxis
autologous hematopoietic stem cell transplantation
chemotherapy-induced nausea and vomiting
fosaprepitant
pediatric
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
05
2020
accepted:
21
08
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
16
7
2021
Statut:
epublish
Résumé
High-dose myeloablative conditioning prior to autologous hematopoietic stem cell transplantation (autoHSCT) in pediatric patients is usually highly emetogenic. The antiemetic neurokinin-1 receptor antagonist fosaprepitant was safe and effective in children receiving highly emetogenic chemotherapy. Data on fosaprepitant during autoHSCT in children are currently not available. A total of 35 consecutive pediatric patients, who received an antiemetic prophylaxis with fosaprepitant (4 mg/kg; single dose, max. 1 x 150 mg/kg BW) and ondansetron (24-hours continuous infusion; 8-32 mg/24h) or granisetron (2 x 40 µg/kg∙d Clinical adverse events and clinically relevant increases/decreases of laboratory markers were similarly low and did not significantly differ between the two study groups ( The fosaprepitant-based antiemetic prophylaxis was safe, well tolerated and significantly reduced vomiting in children undergoing highly emetogenic chemotherapy prior to autoHSCT. Prospective randomized trials are necessary to confirm these results.
Sections du résumé
BACKGROUND
BACKGROUND
High-dose myeloablative conditioning prior to autologous hematopoietic stem cell transplantation (autoHSCT) in pediatric patients is usually highly emetogenic. The antiemetic neurokinin-1 receptor antagonist fosaprepitant was safe and effective in children receiving highly emetogenic chemotherapy. Data on fosaprepitant during autoHSCT in children are currently not available.
METHODS
METHODS
A total of 35 consecutive pediatric patients, who received an antiemetic prophylaxis with fosaprepitant (4 mg/kg; single dose, max. 1 x 150 mg/kg BW) and ondansetron (24-hours continuous infusion; 8-32 mg/24h) or granisetron (2 x 40 µg/kg∙d
RESULTS
RESULTS
Clinical adverse events and clinically relevant increases/decreases of laboratory markers were similarly low and did not significantly differ between the two study groups (
CONCLUSION
CONCLUSIONS
The fosaprepitant-based antiemetic prophylaxis was safe, well tolerated and significantly reduced vomiting in children undergoing highly emetogenic chemotherapy prior to autoHSCT. Prospective randomized trials are necessary to confirm these results.
Identifiants
pubmed: 33061297
doi: 10.2147/DDDT.S260887
pii: 260887
pmc: PMC7524181
doi:
Substances chimiques
Antiemetics
0
Morpholines
0
Serotonin 5-HT3 Receptor Antagonists
0
fosaprepitant
6L8OF9XRDC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3915-3927Informations de copyright
© 2020 Cabanillas Stanchi et al.
Déclaration de conflit d'intérêts
All authors declare that they have no conflicts of interest.
Références
Bone Marrow Transplant. 2004 Dec;34(11):963-8
pubmed: 15489869
Bone Marrow Transplant. 2017 Sep;52(9):1294-1299
pubmed: 28581463
Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46
pubmed: 16221053
Pediatr Transplant. 2004 Jun;8 Suppl 5:28-32
pubmed: 15125703
Pediatr Blood Cancer. 2011 Aug;57(2):191-8
pubmed: 21465637
Support Care Cancer. 2017 Jan;25(1):323-331
pubmed: 27565788
Patient Prefer Adherence. 2013 May 07;7:391-400
pubmed: 23687442
Pediatr Blood Cancer. 2017 Oct;64(10):
pubmed: 28453189
Pediatr Int. 2019 Mar;61(3):235-239
pubmed: 30615239
J Neurooncol. 2016 Jan;126(1):81-90
pubmed: 26608522
Cochrane Database Syst Rev. 2015 Oct 05;(10):CD006301
pubmed: 26436598
BMC Cancer. 2019 Nov 15;19(1):1118
pubmed: 31730451
J Oncol Pharm Pract. 2016 Jun;22(3):416-22
pubmed: 25956421
Pharmacotherapy. 2006 Sep;26(9):1221-31
pubmed: 16945043
J Pediatr Pharmacol Ther. 2014 Apr;19(2):127-31
pubmed: 25024673
Oncologist. 2015 Apr;20(4):450-8
pubmed: 25795636
Biol Blood Marrow Transplant. 2001;7(11):596-603
pubmed: 11760147
J Pediatr Hematol Oncol. 2018 Oct;40(7):527-531
pubmed: 29794645
Biol Blood Marrow Transplant. 1999;5(6):386-93
pubmed: 10595816
Drug Des Devel Ther. 2019 Sep 30;13:3439-3451
pubmed: 31686784
J Cancer Res Clin Oncol. 2020 Apr;146(4):1089-1100
pubmed: 32056007
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):584-589
pubmed: 28694084
Br J Clin Pharmacol. 2017 Oct;83(10):2148-2162
pubmed: 28470980
Cochrane Database Syst Rev. 2017 Apr 13;4:CD008216
pubmed: 28407197
Ann Oncol. 2000 Nov;11(11):1451-62
pubmed: 11142486
Bone Marrow Transplant. 2002 Jul;30(2):119-24
pubmed: 12132051
Lancet Oncol. 2014 Sep;15(10):1157-67
pubmed: 25126964
Pediatr Blood Cancer. 2019 Mar;66(3):e27551
pubmed: 30426714
Biol Blood Marrow Transplant. 2018 Oct;24(10):2065-2071
pubmed: 29906570
Pediatr Clin North Am. 2010 Feb;57(1):47-66
pubmed: 20307711